• Vaccine Name: live attenuated Brucella abortus strain 19 cyclic beta-1,2-glucan synthetase mutant vaccine
• Target Pathogen: Brucella spp.
• Target Disease: Brucellosis
• Vaccine Ontology ID: VO_0009133
• Type: Live attenuated vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Host Species as Laboratory Animal Model: Mus musculus; HeLa cells
• Antigen: cyclic beta-1,2-glucan synthetase mutant (cgs mutant)
• Preparation: Live attenuated mutant strain with deletion of cyclic beta-1,2-glucan synthetase gene. (Briones et al, 2001)
• Description: A cyclic beta-1,2-glucan synthetase mutant was generated from the Brucella abortus attenuated vaccinal strain 19 (S19) to investigate its role in virulence and vaccine efficacy. Efficacy: The mutant was completely cleared from mouse spleens after 4 weeks but retained full protective ability against virulent Brucella abortus strain 2308 challenge. Immune response: The mutant induced equivalent spleen gamma interferon mRNA and IgG2a anti-LPS antibody levels compared to parental S19 strain, but lower IgG1 anti-LPS antibody titers, suggesting a relatively exclusive Th1 immune response. (Briones et al, 2001)

Mouse Response

• Host cell type: HeLa
• Immune Response: The mutant induced equivalent spleen gamma interferon mRNA and IgG2a anti-LPS antibody levels compared to parental S19 strain, but lower IgG1 anti-LPS antibody titers, suggesting a relatively exclusive Th1 immune response. (Briones et al, 2001)
• Efficacy: The mutant was completely cleared from mouse spleens after 4 weeks but retained full protective ability against virulent Brucella abortus strain 2308 challenge. (Briones et al, 2001)
• Description: Virulence was assessed by bacterial clearance from mouse spleens and intracellular replication in HeLa cells; immune response was evaluated by measuring spleen gamma interferon mRNA and anti-lipopolysaccharide IgG2a and IgG1 antibody titers in mice. (Briones et al, 2001)